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Abstract
Background: GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative are working in partnership to
develop a malaria vaccine to protect infants and children living in malaria endemic regions of sub-Saharan Africa,
which can be delivered through the Expanded Programme on Immunization. The RTS,S/AS candidate vaccine has
been evaluated in multiple phase I/II studies and shown to have a favourable safety profile and to be well-
tolerated in both adults and children. This paper details the design of the phase III multicentre efficacy trial of the
RTS,S/AS01 malaria vaccine candidate, which is pivotal for licensure and policy decision-making.
Methods: The phase III trial is a randomized, controlled, multicentre, participant- and observer-blind study on-
going in 11 centres associated with different malaria transmission settings in seven countries in sub-Saharan Africa.
A minimum of 6,000 children in each of two age categories (6-12 weeks, 5-17 months) have been enrolled.
Children were randomized 1:1:1 to one of three study groups: (1) primary vaccination with RTS,S/AS01 and booster
dose of RTS,S/AS01; (2) primary vaccination with RTS,S/AS01 and a control vaccine at time of booster; (3) primary
vaccination with control vaccine and a control vaccine at time of booster. Primary vaccination comprises three
doses at monthly intervals; the booster dose is administered at 18 months post-primary course. Subjects will be
followed to study month 32. The co-primary objectives are the evaluation of efficacy over one year post-dose 3
against clinical malaria when primary immunization is delivered at: (1) 6-12 weeks of age, with co-administration of
DTPwHepB/Hib antigens and OPV; (2) 5-17 months of age. Secondary objectives include evaluation of vaccine
efficacy against severe malaria, anaemia, malaria hospitalization, fatal malaria, all-cause mortality and other serious
illnesses including sepsis and pneumonia. Efficacy of the vaccine against clinical malaria under different
transmission settings, the evolution of efficacy over time and the potential benefit of a booster will be evaluated.
In addition, the effect of RTS,S/AS01 vaccination on growth, and the safety and immunogenicity in HIV-infected
and malnourished children will be assessed. Safety of the primary course of immunization and the booster dose
will be documented in both age categories.
Conclusions: This pivotal phase III study of the RTS,S/AS01 candidate malaria vaccine in African children was
designed and implemented by the Clinical Trials Partnership Committee. The study will provide efficacy and safety
data to fulfil regulatory requirements, together with data on a broad range of endpoints that will facilitate the
evaluation of the public health impact of the vaccine and will aid policy and implementation decisions.
Trial registration: Clinicaltrials.gov NCT00866619
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Background
The past decade has seen unparalleled advances in the
fight against malaria, and numerous public and private
organizations are contributing hundreds of millions of
dollars to malaria infection and disease research [1,2].
Malaria control interventions, including the use of long-
lasting insecticide-treated nets and artemisinin-based
combination treatment, have been broadly implemented
[1], with some countries recently reporting an associated
fall in malaria incidence [3]. Nevertheless, malaria con-
tinues to impose a considerable burden of morbidity
and mortality, most significantly in young children, and
reducing this burden in this population is, therefore, a
public health priority in sub-Saharan Africa [4,5].
A safe and affordable vaccine would be a valuable
addition to existing control measures. GlaxoSmithKline
(GSK) Biologicals has been working towards the devel-
opment of a safe and effective malaria vaccine for more
than 20 years and has developed a candidate Plasmo-
dium falciparum malaria vaccine, RTS,S/AS01, which is
currently in phase III clinical trials in infants and chil-
dren living in malaria-endemic regions of sub-Saharan
Africa [6]. It is intended that the vaccine will be deliv-
ered through the Expanded Programme on Immuniza-
tion (EPI) to leverage the vaccine delivery systems used
to routinely administer immunizations to young
children.
The candidate malaria vaccine targets the pre-erythro-
cytic stage of the P. falciparum parasite. It contains the
RTS,S antigen and is formulated with a novel proprie-
tary Adjuvant System (AS). Clinical trials of the vaccine
formulated with closely related Adjuvant Systems -
AS01 or AS02 - have been conducted, and the RTS,S/
AS01 formulation has been selected for phase III devel-
opment based on comparative clinical studies [7,8].
AS01 is composed of liposomes and the immunomodu-
latory molecules, 3-O-desacyl-4’-monophosphoryl lipid
A (MPL) and QS21 [9].
A series of phase II clinical trials have been conducted
to determine the safety, immunogenicity and efficacy of
the RTS,S/AS vaccine in the target population of chil-
dren at high risk of the disease. A proof-of-concept
study in children aged 1-4 years in Mozambique showed
that the RTS,S/AS02 vaccine was well-tolerated, with a
vaccine efficacy of 35% against clinical malaria and 49%
against severe malaria over 18 months [10,11]. Subse-
quent studies in infants have shown that the vaccine is
well-tolerated and immunogenic in infants from 6 weeks
of age, and can be successfully integrated into the EPI
schedule [12,13]. Phase II studies have estimated the
efficacy of the RTS,S/AS01 vaccine against clinical
malaria to be 53% over eight months in 5-17 month old
children and 59% over 17 months in 6-12 week old
infants [14,15]. At the end of phase II, a pooled analysis
of all paediatric safety data was conducted to support
the progression of the RTS,S/AS candidate vaccine into
large scale phase III clinical testing in Africa. Analysis of
the extensive safety database of RTS,S/AS confirmed the
favourable safety profile of the vaccine in children and
infants living in malaria endemic regions in sub-Saharan
Africa [Vekemans, Guerra, Lievens, Benns, Lapierre,
Leach, Verstraeten: Pooled safety analysis of paediatric
phase II RTS,S/AS malaria candidate vaccine trials,
submitted].
The licensure claim of vaccine efficacy will be based
principally on a large phase III clinical trial. This paper
describes the overall design of the phase III multicentre
efficacy study of the candidate RTS,S/AS01 malaria vac-
cine. The aims of this study are two-fold. Firstly, it will
provide pivotal efficacy and safety data to support regu-
latory approval of the vaccine by the European Medi-
cines Agency (EMA) and African national regulatory
authorities and to facilitate pre-qualification by the
World Health Organization (WHO). Secondly, it
includes a broad range of endpoints that will allow
assessment of the full public health impact of the vac-
cine. This information will be required to support a
recommendation by the WHO and implementation
decisions by local policy makers, and is key to ensure
uptake of the vaccine following licensure [16]. Measures
of vaccine efficacy on various disease endpoints in the
phase III study may be utilized in an assessment of
health economics. Additional data to support the full
health economic evaluation are being collected in ancil-
lary studies, such as assessment of quality of life, subject
preferences, the measurement of resource utilization
and direct and indirect costs, details of which will be
described in separate publications.
The population of the phase III trial mirrors as closely
as possible the population of children who usually
attend EPI visits. Low-birth-weight infants, malnour-
ished children, and HIV-infected children were eligible.
For safety reasons, those that were critically sick were
excluded: in particular any child who required hospital
admission or had an advanced stage of HIV disease
(WHO classification grade 3 or 4). A dedicated phase III
study will assess safety and immunogenicity in children
exposed to HIV (NCT01148459). Two further studies
will evaluate the safety and immunogenicity of RTS,S/
AS01: the first in co-administration with rotavirus and
Streptococcus pneumoniae vaccines, which are expected
to become part of the EPI program in the near future,
and the second with three lots of RTS,S/AS01 vaccine
in order to demonstrate lot-to-lot consistency.
Clinical development of the RTS,S/AS01 vaccine is
undertaken in a public private partnership between
GlaxoSmithKline and the PATH Malaria Vaccine Initia-
tive (MVI), which receives funding from the Bill and
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Melinda Gates Foundation. The trial is also supported
by the Malaria Clinical Trials Alliance (MCTA), an Afri-
can-led organization that aims to build capacity and
share best practice for the conduct of clinical trials. This
multi-centre efficacy trial was designed by the Clinical
Trials Partnership Committee (CTPC), which has mem-
bership representing each of the academic institutions
participating in trial conduct, GSK Biologicals and MVI.
Methods
Study design
This is a phase III, randomized, controlled, multicentre,
participant- and observer-blind study. Enrolment
occurred between May 2009 and February 2011. Follow
up is currently on-going at 11 centres covering a wide
range of transmission settings in seven countries in sub-
Saharan Africa (Figure 1). The study is conducted in
accordance with the current Declaration of Helsinki,
International Committee on Harmonization Good Clini-
cal Practice guidelines and local rules and regulations of
each country. The study is overseen by an Independent
Data Monitoring Committee (IDMC), assisted by a
Local Safety Monitor at each centre. Approval was
obtained from 56 institutional review boards and
national Regulatory Authorities. Prior to study inclusion,
parents or guardians of all participants provided signed/
finger-printed and witnessed informed consent.
An overview of the study design is shown in Figure 2.
Children were enrolled in two age categories: 6-12
weeks old and 5-17 months old. A minimum of 6,000
children in both age categories (to a total maximum of
16,000 children) have been enrolled and randomized
1:1:1 to one of three study groups for primary and boos-
ter vaccination (Table 1). The control vaccine given
depends upon the age of the child at enrolment (Table
1). Children in the younger age category receive their
primary vaccination course at 6, 10 and 14 weeks of age,
in co-administration with the other vaccines usually
administered at these EPI visits (Table 1). The specified
age range of 6-12 weeks at first vaccination allows for
some flexibility in this schedule to align with local
guidelines and practice. Bacillus-Calmette-Guérin (BCG)
vaccine, neonatal dose of oral polio vaccine (OPV),
measles vaccine and yellow fever vaccine are given
according to local policy.
Primary immunizations are administered by intramus-
cular injection into the antero-lateral thigh (children
aged 6-12 weeks) or the left deltoid (children aged 5-17
months); all children receive the booster injection in the
left deltoid. Neither the study subjects and their par-
ents/guardians nor the study personnel involved in eva-
luation of the study endpoints are aware of the group
allocation of the subjects. Because the study vaccines
differ in appearance, the study staff responsible for their
preparation and administration is aware of treatment
allocation and therefore perform no other role in the
trial.
There is no routine testing for HIV infection in this
study, HIV tests are performed only if clinically indi-
cated. Voluntary counselling and testing, Highly Active
Antiretroviral Therapy (HAART) and Prevention of
Mother to Child Transmission (PMCT) are available at
all study centres according to national policies.
In accordance with national policies, all centres use
artemisinin-based combination therapy (ACT) as first
line treatment for malaria cases. The use of insecticide-
treated bed nets is optimized at all centres by the close
collaboration between research staff and malaria control
program managers or through distribution at screening.
Other control interventions such as intermittent preven-
tive treatment in infants (IPTi) and indoor residual
spraying (IRS) are not currently part of policy in the
study areas, but if this changes during the trial, their use
will be recorded.
The overall sample size has taken into account the
recent description of falling rates of malaria disease in
several parts of Africa. To be assured of meeting the pri-
mary endpoints, conservative rates of disease were
applied in the calculation of sample size and a case dri-
ven approach selected [3]. To control for the co-primary
endpoint in each of the two age categories, evaluations
will be performed at a 2.5% alpha level (Bonferroni cor-
rection). Assuming an attack rate in controls of 10/100
children years at risk (cyr), a 12 months follow up per-
iod, a true vaccine efficacy of 30% and a drop-out rate
of 10% then the sample size of 6000 children in each
age category has 90% power to detect a lower limit of
the 97.5% CI around estimated VE above 0%. In the
event that the attack rate is lower than anticipated, the
analysis will be postponed until 450 cases have accumu-
lated. Due to the uncertainty around the rate of severe
malaria disease according to the case definitions used in
the trial, the total sample size is up to 16000 children
and the analysis will be conducted for both age cate-
gories pooled when 250 episodes have accumulated.
This gives 80% power to detect 30% VE with a lower
limit of the 95% CI above 0% or assuming 50% VE 90%
power to detect a lower limit of the 95% CI above 25%.
Study subjects
Inclusion and exclusion criteria are shown in Table 2.
The aim was to enrol a broad sample of children repre-
sentative of the general population. Exclusion criteria
have been kept to a minimum to mirror the general
population as far as possible whilst minimizing partici-
pant safety risk exposure. Children with a history of
simple febrile seizure, malnourished children not requir-
ing hospitalization and HIV-infected children (other
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than those with HIV disease stage 3 or 4 severity as
defined by the WHO 2005) were not excluded from
study participation.
Study vaccines
The candidate malaria vaccine is RTS,S/AS01 (GSK Biolo-
gicals, Rixensart, Belgium). The RTS,S antigen is a hybrid
recombinant protein consisting of the P. falciparum cir-
cumsporozoite (CS) protein central tandem repeat and
carboxy-terminal regions fused to the amino-terminus of
the S antigen of hepatitis B virus (HBsAg). The vaccine is
formulated with the AS01 Adjuvant System.
The choice of comparator vaccines was guided by the
need to offer potential benefit to the control group
Southern partners Northern partners
Institut de Recherche en Science de la Santé, Burkina 
Faso
Albert Schweitzer Hospital, Gabon
Kintampo Health Research Centre, Ghana
Kumasi Centre for Collaborative Research, Ghana
School of Medical Sciences, Kwame Nkrumah 
University of Science and Technology, Ghana
KEMRI/CDC Research and Public Health 
Collaboration, Kenya
KEMRI-Walter Reed Project, Kenya
KEMRI-Wellcome Trust Research Programme, Kenya
University of North Carolina Project, Malawi
Centro de Investigação em Saude de Manhiça, 
Mozambique
Ifakara Health Institute, Tanzania
National Institute of Medical Research, Tanzania
Prince Leopold Institute of Tropical Medicine, 
Belgium
University of Copenhagen, Denmark
Bernhard Nocht Institute, Germany
University of Tübingen, Germany
University of Barcelona, Spain
Swiss Tropical Institute, Switzerland
London School of Hygiene and Tropical 
Medicine, UK
Centre for Disease Control and Prevention, USA
University of North Carolina at Chapel Hill, USA
Walter Reed Army Institute of Research, USA
Map from www.mara.org.za
Figure 1 Study centers and clinical trial partners.
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without compromising the evaluation of study end-
points. The pros and cons of a number of options were
debated and consensus reached by the CTPC after tak-
ing into account regional epidemiology and EPI pro-
grams. Rabies vaccine was chosen as the control for the
5-17 month age category because of the high burden of
rabies across all of sub-Saharan Africa, its high fatality
rate and the particular risk to children [17-19]. Rabies
vaccine has been evaluated according to several different
vaccination schedules, and the 0, 1, 2-month schedule
used in this trial is expected to produce acceptable anti-
body titers and provide protection. Rabies vaccine was
not appropriate for children in the 6-12 week age cate-
gory because co-administration with EPI antigens has
not been evaluated. For the 6-12 week age group, con-
sideration was given to vaccines against S. pneumoniae,
which is a common cause of pneumonia in children in
Africa. The reasons for not selecting pneumococcal vac-
cines were that they were expected to be implemented
as policy in some countries prior to the enrolment and
R R R R
C C C C
C3C
R3R
M0 M2M1 M3 M14 M20 M21 M32
Screening
BSBS BS BS BS
Randomization
1:1:1
Primary 
analysis
Final 
analysis
R R R C
R3C
R: Vaccination with RTS,S/AS01E BS: Blood sample
C: Vaccination with control vaccine M: Study Month
Figure 2 Study design.
Table 1 Treatment groups and vaccination schedule
Primary vaccination: 0, 1, 2 months Booster vaccination: month 20
Children 5-17 months of age
“R3R” group RTS,S/AS01 RTS,S/AS01
“R3C” group RTS,S/AS01 Control (MCC vaccine)
“C3C” group Control (rabies vaccine) Control (MCC vaccine)
Children 6-12 weeks of age
“R3R” group RTS,S/AS01 + DTPwHepB/Hib + OPV RTS,S/AS01 + OPV
“R3C” group RTS,S/AS01 + DTPwHepB/Hib + OPV Control (MCC vaccine) + OPV
“C3C” group Control (MCC vaccine) + DTPwHepB/Hib + OPV Control (MCC vaccine) + OPV
MCC: Meningococcal C conjugate vaccine - Meningitec™ (Wyeth), NeisVac-C™ (Baxter) or Menjugate™ (Novartis)
Cell culture rabies vaccine - human diploid cell rabies vaccine (Imovax™, Sanofi Pasteur), purified chick embryo cell culture vaccine (Rabipur™/Rabavert™,
Novartis) or purified Vero cell culture rabies vaccine (VeroRab™, Sanofi Pasteur)
DTPwHepB/Hib - Tritanrix HepB™ and Hiberix™ (GSK Biologicals)
OPV: Oral polio vaccine - Polio Sabin™ (GSK Biologicals)
Each child will receive all three doses of rabies vaccine or MCC vaccine from the same manufacturer
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so would not provide additional benefit. In addition,
there is a poorly understood interaction between malaria
and pneumococcal infections. In paediatric hospital
admissions, pneumonia and malaria co-occur more
often than expected by chance [20]. This may be due to
the overlapping clinical symptoms and signs of pneumo-
nia and malaria, or the immunosuppressive effect of
malaria infection on pneumococcal pneumonia [21].
The careful characterization of both malaria and pneu-
monia in this trial will also allow the study of the effect
of malaria control on the incidence of pneumococcal
disease [22]. Meningococcal disease in Africa is most
commonly due to serogroup A, however there currently
is no meningococcal A vaccine licensed for use in
infants. Meningococcal C conjugate vaccine was chosen
because it is acceptably safe and immunogenic when
administered according to a 0, 1, 2-month schedule, can
be safely co-administered with the other vaccines and
will not compromise the analysis of the study endpoints.
Although meningitis C is not common in sub-Saharan
Africa outbreaks have been reported [23-25] and, there-
fore, the vaccine may provide some benefit to study
subjects.
Endpoint data collection
Clinical malaria cases are detected through passive sur-
veillance at local health facilities. A blood sample for
evaluation of malaria parasites is taken from all children
with axillary temperature of ≥37.5°C or those reported
to have had a fever within 24 hours of presentation. All
subjects attending hospital emergency departments in
the study areas are evaluated as potential cases of severe
malaria following an algorithm, and case assessment is
standardized across centers [22]. The algorithm also
allows identification of cases of anaemia, sepsis and
pneumonia.
Two cross-sectional surveys will be conducted at study
months 20 and 32 to assess vaccine efficacy against pre-
valent parasitaemia and anaemia. Data will be collected
on potential covariates which may be included in the
analysis of efficacy. These are bed net usage by direct
observation, application of IRS, administered doses of
IPTi, distance from nearest inpatient health facility, dis-
tance from nearest outpatient health facility, pneumo-
coccal/Hib vaccination status, ethnicity, anthropometric
measurements and feeding history.
Full quality systems are in place for all laboratory tests
in the trial and these are described in a companion
paper [26]. Anti-CS and anti-HB antibody titers are
measured at all blood sampling time points in a subset
of children from both age categories at all sites (See
Figure 2 for blood sampling time points). In addition, a
nested case control study will evaluate the association
between CS-antibody response and protection against
malarial disease. In a safety and immunogenicity trial of
RTS,S/AS01 co-administered with EPI vaccines, pre-
defined non-inferiority criteria compared to control
were met for all the DTPwHepB/Hib+OPV, measles and
yellow fever antigens, with the exception of polio 3
viruses when RTS,S/AS01 was administered at 0, 1, 2-
Table 2 Inclusion and exclusion criteria
Inclusion
criteria
Male and female children aged 6-12 weeks or 5-17 months at time of first vaccination
Children in 6-12 week age category must be more than 28 days old at screening and must not have received previous
vaccination against diphtheria, tetanus, pertussis or Hemophilus influenzae type B
Exclusion
criteria
Acute disease at time of enrolment
Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality
Major congenital defect
Malnutrition requiring hospitalization
Hb ≤8 g/dL with clinical signs of heart failure or severe respiratory distress OR Hb ≤5 g/dL
Currently meeting WHO criteria for stage III or IV severity HIV disease
History of allergic reactions, significant IgE-mediated events or anaphylaxis to previous immunizations
History of allergic disease or reactions likely to exacerbated by any component of the vaccine
History of a neurological disorder or atypical febrile seizure
Concurrently participating in another clinical study of a drug or vaccine unlicensed for that indication, except studies aiming to
improve treatment or management of severe malaria
Use of a drug or vaccine unlicensed for that indication other than study vaccines within 30 days preceding the first dose of study
vaccine or planned use during the study period
Previous participation in another malaria vaccine trial
Receipt of a vaccine within the preceding 7 days
Other factors that the investigator considers would increase the risk of an adverse outcome or result in incomplete or poor quality
data
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months [27]. Although a post-hoc analysis showed that
differences were explained by pre-vaccination titres,
additional data will be collected in this phase III study.
Titres will be assessed in a subset of infants in the 6-12
week age category at each site at three time points:
study start, one month post primary vaccination, and
one month post OPV booster vaccination.
Serious adverse events (SAE) are collected for all sub-
jects for the entire study period. Completeness of SAE
reporting is strengthened by monthly visits of field
workers to the children’s homes. SAEs are defined as
AEs resulting in death, which are life-threatening or
require hospitalization or prolongation of existing hospi-
talization or those that result in disability or incapacity.
Unsolicited AEs occurring during the 30 days after each
vaccine dose and solicited AEs occurring during the
seven days after each vaccine dose are collected for the
first 200 children enrolled in each age category at each
centre. In the remainder of children, only AEs that are
considered to be related to vaccination or those result-
ing in study withdrawal are recorded. Investigators will
grade all AEs and SAEs as mild, moderate or severe
based on a scale of interference with normal daily activ-
ities, and assess the relationship to vaccination.
Seizures occurring within 30 days of vaccination are
also required to be reported as SAEs. For seizures
occurring within seven days of vaccination, an analysis
will be performed based on the Brighton Collaborations
guidelines, which captures the features of the seizure
and classifies the level of diagnostic certainty [28]. In
the first 200 subjects enrolled at each site in the six to
12 weeks age category an analysis of rashes and muco-
cutaneous diseases within 30 days of vaccination will be
performed based on the Brighton Collaboration Guide-
lines [29]. Due to a theoretical concern that the use of
new adjuvanted vaccines may interfere with immunolo-
gical self-tolerance, regulatory authorities have requested
data collection on immune-mediated diseases (IMD).
Therefore, all IMDs are reported as SAEs for all subjects
over the entire study period. Diagnostic support at a
referral laboratory is provided.
Solicited local (injection site) AEs recorded are pain,
swelling and redness; grading of symptoms is on a scale
of 0-3. Solicited general AEs recorded are drowsiness,
fever, irritability/fussiness and loss of appetite; intensity
of symptoms (except fever) are graded on a scale of 0-3
based on interference with normal daily activities; fever
is defined as axillary temperature ≥37.5°C. Methods
have been fully described previously [30].
Verbal autopsies are carried out for all children who
die outside a health facility to ascribe the cause of
death. The questionnaire used is based on the
INDEPTH standard and adapted to be locally appropri-
ate [31]. At study end, all forms will be read by a central
panel to attribute cause of death. As a general health
indicator, growth is monitored throughout the study
according to standardized methods. The length (<2
years of age) and height (≥2 years of age), weight and
mid-upper arm circumference are measured at first vac-
cination and at study months 3, 20 and 32.
Safety and immunogenicity will be described in the
special sub-populations of malnourished and HIV-
infected children. Weight at enrolment will be used to
determine a subset of children who are low weight for
age (weight for age z-score ≤-2) and very low weight for
age (weight for age z-score ≤-3). HIV infections known
at enrolment or diagnosed during the trial are recorded.
Study objectives and case definitions
Primary efficacy objectives
The co-primary objectives of the study are efficacy over
1 year post-dose 3 against clinical malaria when primary
immunization starts at: (1) 6-12 weeks of age, with co-
administration of DTPwHepB/Hib and OPV antigens;
(2) 5-17 months of age (Table 3). Clinical malaria was
selected as the primary endpoint for this trial. There is
an enormous burden of disease in sub-Saharan Africa
associated with clinical malaria that puts substantial
demands on the health services of these countries [32].
Table 3 Study objectives
Efficacy Efficacy against clinical malaria over 1 year in
children aged 6-12 weeks at first vaccination (co-
administration of DTPwHepB/Hib)1
Efficacy against clinical malaria over 1 year in
children aged 5-17 months at first vaccination1
Efficacy against severe malaria
Prevention of anaemia (incident severe anaemia;
prevalent moderate and severe anaemia)
Prevention of malaria hospitalization
Evolution over time of efficacy following the primary
vaccination course
Additional benefit of a booster dose
Efficacy in different transmission settings
Efficacy against parasite prevalence
Efficacy against other serious illnesses (medical
hospitalization, sepsis and pneumonia)
Efficacy against fatal malaria and all-cause mortality
Effect on growth
Gender-specific efficacy2
Immunogenicity Immunogenicity of a primary vaccination course
Immunogenicity of a booster dose
Immunological correlates of protection
Immunogenicity of the oral polio vaccine when co-
administered with RTS,S/AS01
Safety Safety of a primary vaccination course
Safety of a booster dose
Special
populations
Immunogenicity and safety in HIV-infected children
Immunogenicity and safety in low weight for age
children
1 Represent the primary objectives
2 If important differences in the co-primary objectives are observed between
boys and girls, all primary and secondary efficacy and immunogenicity
endpoints will be presented separately for boys and girls
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It is a serious condition with approximately 2% of cases
progressing to severe and life threatening forms of the
disease [33]. Severe malaria was not selected as the pri-
mary endpoint of the trial because of uncertainty sur-
rounding rates of severe disease. Indeed, malaria
incidence appears to be falling in areas of Africa where
effective malaria control measures, such as insecticide-
treated bed nets and first-line treatment with ACT, have
been implemented [3]. A vaccine that is effective against
clinical malaria is likely to be at least as efficacious
against severe disease.
The primary case definition of clinical malaria upon
which the primary endpoint will be assessed is presented
in Table 4. One of the criteria of the case definition is
that the child is unwell and brought to a health care
facility. This is to ensure that the cases of malaria are
representative of the severity of cases using health ser-
vices and is a measure of public health relevance. It is
likely that most cases of clinical malaria that occur in
the community will present to healthcare facilities
because all children in the study areas have reasonable
access to healthcare, and if any costs are incurred, these
are reimbursed by the study.
Another criterion of the definition is a parasite density
threshold. This has been added to increase the specifi-
city of the case definition. Achieving a balance between
specificity and sensitivity is a major challenge in defining
endpoints in malaria vaccine trials. Low specificity
means that vaccine efficacy is likely to be underesti-
mated, whereas low sensitivity means that the power of
the study will be reduced [34]. Achieving adequate spe-
cificity in the case definition of clinical malaria is diffi-
cult, as the symptoms of malaria overlap with those of
many other common febrile childhood illnesses. It is
well recognized that as parasite density increases, the
likelihood that symptoms are caused by P. falciparum
infection also increases. A widely-used methodology in
malaria research is applied to calculate the specificity
and sensitivity of clinical case definitions according to
parasite density threshold values [35]. A single parasite
density threshold of 5,000 parasites/μL is employed
across all centres for the primary endpoint to support
pooling of data. This threshold was based on data from
previous studies [35-40], and provides a minimum speci-
ficity of 80% for all transmission settings and age cate-
gories in this trial. By adding the requirement for fever
and a parasite density threshold we adhere to the
accepted practice to evaluate malaria disease interven-
tions. However, in the evaluation of IPTi, using case
definitions with varying parasite density thresholds has
not yielded the expected increase in specificity reflected
in the estimate of effect [41]. In the case of an interven-
tion that is equally protective against symptomatic para-
sitaemia and asymptomatic parasitaemia less specific
definitions for malaria disease may not significantly
impact efficacy estimates. This appears to be the case
for this pre-erythrocytic vaccine [14,42].
The principal analysis for the determination of the pri-
mary endpoint is protection against first or only epi-
sodes of malaria using a hazard ratio estimated from
Cox regression model. This will be adjusted for centres
to control for differences in malaria transmission
between centres. The statistical methodology is further
discussed in the companion paper [43].
Secondary efficacy objectives
A wide range of secondary objectives are included in this
trial to support a full evaluation of the potential public
health impact of the vaccine and to aid policy and imple-
mentation decisions. Secondary efficacy objectives are
shown in Table 3. The trial will look at the full spectrum
of disease manifestations from clinical malaria to severe
and fatal disease. Case definitions for secondary end-
points relating to disease manifestations are shown in
Tables 4 and 5, with the exception of severe malaria.
Severe malaria is a key endpoint in this study and is
described in further detail in a companion paper [22].
The case definitions have been selected to be consis-
tent with usual practice wherever possible to allow
Table 4 Case definition of clinical malaria
Criterion Primary definition Secondary definition 1 Secondary definition 2 Secondary definition 3
Threshold of P.
falciparum asexual
parasitaemia
>5,000 parasites/μL >0 parasites/μL >500 parasites/μL >20,000 parasites/μL
Fever axillary temperature
≥37.5°C
axillary temperature ≥37.5°Cor history
of fever within 24 h of presentation
axillary temperature
≥37.5°C
axillary temperature
≥37.5°C)
Case detection Child is unwell and
brought to healthcare
facility
Child is unwell and brought to
healthcare facility
Child is unwell and
brought to healthcare
facility
Child is unwell and
brought to healthcare
facility
Other OR
Meets primary case
definition of severe
malaria1
1 Refer to [22] for primary definition of severe malaria
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generalizability of trial findings and comparability with
other interventions. Where applicable for fuller interpre-
tation of the data, multiple case definitions for a given
endpoint have been used. For example, three secondary
definitions of clinical malaria will be analysed (Table 4).
The first is highly sensitive and includes detection of
any parasite level, plus a history of fever, and is not lim-
ited to measured fever at presentation. This definition
mirrors the children who are treated under current
WHO guidelines and will be important for consideration
of the impact of the vaccine on disease burden and in
health economic analyses. The second case definition is
designed for the analysis of infants; the lower parasite
density threshold of >500 parasites/μL may be appropri-
ate for this age group [36,40]. The third definition, with
a high parasite density threshold, is included because it
is highly specific.
This study aims to characterize the potential indirect
benefits of malaria control through vaccination using
the complete morbidity data set collected. Trials with
insecticide-treated bed nets have shown a reduction in
all-cause mortality that is not solely accounted for by
malaria-specific mortality characterized on verbal
autopsy [44,45]. There was an indication of indirect ben-
efits associated with RTS,S/AS vaccination in phase II
trials; in one study, the overall trend of fewer SAEs in
vaccine recipients was only partly accounted for by
malaria events [14], and in another study, pneumonia
hospitalization was less common in vaccine recipients
[13]. Specifically, the possible vaccine benefit on bacter-
aemia/sepsis and pneumonia will be investigated. The
evaluation and definition of pneumonia is based on the
extensive methodological and case definition work done
to support paediatric pneumococcal conjugate vaccine
trials [46].
How the spectrum of clinical benefits provided by vac-
cination evolves with time will be critically important for
policy decisions. This trial will provide information up
to 2.5 years after a primary vaccination course. The eva-
luation of efficacy over time is complicated; children
progressively acquire natural immunity as they age and
therefore whilst the biological action of the vaccine may
Table 5 Case definitions of secondary efficacy endpoints
Definition 1 Other definitions
Incident
severe
anaemia1
Hb <5.0 g/dL identified on morbidity surveillance in association
with P falciparum parasitaemia >5000 parasites/μL
Hb <5.0 g/dL identified on morbidity surveillance
PLUS
1. P falciparum parasitaemia >0 parasites/μL
OR
2. No parasitaemia
Prevalent
anaemia1
Hb <5.0 g/dL identified at cross sectional survey Hb <8.0 g/dL identified at cross sectional survey
Malaria
hospitalization
Medical hospitalisation2 in association with P falciparum
parasitaemia >5000 parasites/μL
P falciparum infection is sole or major cause of hospitalization
on investigators’ clinical judgement
All
hospitalization
Medical hospitalization2
Bacteremia/
Sepsis
Positive blood culture7
Pneumonia Cough or difficulty breathing (on history)
Tachypnoea (≥50 breaths per minute in children <1 year, ≥40
breaths per minute in children ≥1 year)
Lower chest wall in-drawing
As definition 1, PLUS
1. Chest X-ray consolidation or pleural effusion on a chest X-ray
taken within 72 h of admission
OR
2. Chest X-ray consolidation or pleural effusion or other
infiltrates on a chest X-ray taken within 72 h of admission
OR
3. Oxygen saturation <90%
Fatal malaria Fatal case of severe malaria according to primary case definition
3,4
Fatal case of severe malaria according to secondary definitions
3,4
All-cause
mortality
Death due to any cause5 Death due to medical cause5,6
1 Severe anaemia is defined as Hb <8 g/dL and very severe anaemia is defined as Hb <5 g/dL according to WHO/IVR report (WHO/IVR Malaria Vaccine Advisory
Committee meeting 2004)
2 Excludes planned, surgical and trauma related admissions
3 Refer to [23] for primary and secondary definitions of severe malaria
4 Restricted to children fully evaluated as inpatients and excludes diagnoses made by verbal autopsy
5 Includes deaths in hospital and in the community
6 Excludes trauma, which may be diagnosed by verbal autopsy
7 A blood culture taken within 72 h of admission is considered positive if: a definite pathogen is isolated or a bacteria that could be either a pathogen or a
contaminant is isolated within 48 hours of incubation and is considered clinically to be a likely pathogen [23].
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persist unchanged the vaccine efficacy that is measured
relative to control will fall. Inclusion of a group that will
receive a booster dose allows the potential benefit of a
primary course plus booster to be measured against
both the comparator and against the primary course
alone.
To support extrapolation of trial results to other
regions, data will be generated from a number of diverse
malaria transmission settings; the participating centers
are shown superimposed on the Mapping Malaria Risk
in Africa (MARA) map of malaria risk in Africa in Fig-
ure 1. Site-specific estimates of efficacy against clinical
malaria will be produced (this is further detailed in a
companion paper [43]).
Conclusion
This pivotal phase III efficacy study of the RTS,S/AS01
candidate malaria vaccine in African children was
designed and implemented by the Clinical Trials Part-
nership Committee. The study design is in full accord
with the conclusions of the WHO expert panel on the
measurement of malaria vaccine efficacy in phase III
clinical trials [47]. The design described here evolved
over approximately five years of planning, through colla-
boration between, and with input from, scientists, regu-
lators, and policy-makers. The study will provide
efficacy and safety data to fulfil regulatory requirements,
and will supply data on a broad range of disease end-
points that will allow evaluation of the public health
impact of the vaccine. Data from the primary analysis of
clinical malaria one year after completion of the primary
immunization course of children aged 5-17 months are
expected to be available in 2012. At the end of the
study in 2015, data will be available on a wide range of
disease endpoints, as well as information on the evolu-
tion of efficacy over time, the potential added benefit of
a booster dose and long-term safety.
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